Hormonal
Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces dose-dependent reductions in body weight (up to 9.8% at 45 mg) and waist circumference, with maximal efficacy observed at higher doses (24-45 mg).
Orforglipron is an oral medication that helps obese adults lose weight and improve metabolic markers like blood sugar and cholesterol. It works by mimicking a natural hormone (GLP-1) to reduce appetite and slow digestion. The higher the dose (up to 45 mg daily), the more weight is lost, with studies showing up to 9.8% body weight reduction. However, higher doses also increase the risk of stomach issues like nausea and diarrhea, which may lead some patients to stop taking it. It is taken once daily without strict fasting requirements, making it more convenient than some injectable alternatives.
Orforglipron demonstrated dose-dependent reductions in body weight from 2.48% at 3 mg to 9.8% at 45 mg... demonstrating a dose-dependent effect (p = 0.008)
Why this rating
Based on a meta-analysis of 5 RCTs with 4410 participants, though heterogeneity was high for some outcomes.
Source
Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis
Ravi Kumar Pandey et al. · Endocrinology Diabetes & Metabolism · 2025
DOI 10.1002/edm2.70134
More from this paper
- Orforglipron significantly improves lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol, independent of weight loss magnitude.Good
- Orforglipron is associated with a dose-dependent increase in gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) and treatment discontinuation rates, particularly at doses of 12 mg and higher.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →